Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410 ...
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on AbSci (ABSI – Research Report) today and set a price target of $7.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback